Le Lézard
Classified in: Health
Subject: AWD

Pilatus Clinical Services - German Subsidiary PCS GMBH Awarded WDL & GDP Certificate


LONDON, March 14, 2018 /PRNewswire/ --

As part of Pilatus Clinical Services ongoing plans to strengthen its position in Europe and as part of establishing a Global footprint, the company has announced that following a recent inspection by the German regulatory authorities, its German facilities in Brandenburg have been granted a WDL/GDP Certificate.

Managing Director, Philipp Hofmann says, "We have now been established and trading since April 4th 2017, but it was imperative that we are geared up to be in a position to operate under this WDL/GDP Certificate. I am proud of the dedication put in by the team to ensure that we received the go ahead from the regulatory authorities in record time."

This will greatly strengthen Pilatus Clinical Services' position in Europe and enhance its access to manufacturers and suppliers in Europe, to transform the service offered to clients.

With Brexit looming, this move will also mitigate any risk of exposure to Pilatus Clinical services and our Clients.

Management of end to end supply chain, so you don't have to worry about it. To find more out about Pilatus Clinical Services, please take a look at our website http://www.pilatusclinicalservices.com/

Contact details for PCS GMBH:
+49-3328-428-9909
[email protected]
http://www.pcs-deutschland.com
PCS GmbH, Mahlowerstr. 249, 14513 Teltow,
Amtsgericht Potsdam| HRB 30039 P | USt-IdNr. DE312595524

SOURCE Pilatus Clinical Services


These press releases may also interest you

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...



News published on and distributed by: